Evidence suggestive of partial lesion remyelination after alemtuzumab therapy has been found by Australian researchers using a unique visual neuronal pathway model. A team at the Sydney Neuroimaging Analysis Centre, and the Australia Brain and Mind Centre, University of Sydney, used measurements of visual evoked potential (VEP) latency as a surrogate marker of myelin integrity/recovery ...
Pro-remyelinating effects of MS therapy seen in visual pathway
By Michael Woodhead
6 Jul 2021